Verona Pharma (VRNA) on Tuesday said it expects Q4 net product sales of $36 million on the back of the commercial launch of Ohtuvayre, a treatment for chronic obstructive pulmonary disease, a lung condition.
Full-year 2024 net product sales are expected to be $42 million, the company said.
Meanwhile, the company said it expected to report $400 million in cash and cash equivalents as of Dec. 31, 2024.
Price: 48.95, Change: +4.14, Percent Change: +9.24
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。